| Ytd | -34.18% | |
| 1y | -74.16% |
| Open | 2.60 | Prev Close | 2.58 | Low | 2.60 | High | 2.60 | Mkt Cap | 196.15M |
| Vol | 6.41K | Avg Vol | 92.17K | EPS | -0.06 | P/E | -43.00 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 0.56 | Inst. Own | 0.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.04 | 200-d Avg | 12.62 | 1yr Est | 0.00 |
MENS News
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
As previously announced, its first core product, Botreso®, has completed four Phase III clinical tri
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostat
Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-drive
Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recen
Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-drive
Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driv
Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-drive
